Investment in biotech/medtech

After raising 1.8M EUR, Cor.Sync's solution for heart attack is undergoing rigorous clinical studies in Brazil, with results expected in approximately seven months.

Now we are raising +1.5 million euros for market entry in Brazil and start a European operation. For the last, we are located at Spartners, the incubator by Servier & BioLabs at the Paris-Saclay Université, that got us close bindings to AP-HP (Assistance Publique - Hôpitaux de Paris) for clinical trials, even though we are seeking more reference hospitals to improve the study relevance. We are also partnering with Paris-Saclay Cancer Cluster, to research and develop new biosensors, aimed for measurement of novel biomarkers, pathogens and MicroRNAs.